Theranexus Société Anonyme (ALTHX.PA)
EUR 0.64
(32.37%)
EUR 0.64
(32.37%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.01 Million EUR | -20.7% |
| 2022 | 6.32 Million EUR | -5.7% |
| 2021 | 6.7 Million EUR | -6.67% |
| 2020 | 7.18 Million EUR | 33.24% |
| 2019 | 5.39 Million EUR | -0.83% |
| 2018 | 5.43 Million EUR | 226.73% |
| 2017 | 1.66 Million EUR | -40.35% |
| 2016 | 2.79 Million EUR | 165.91% |
| 2015 | 1.04 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 4.26 Million EUR | 0.0% |
| 2023 Q2 | 5.33 Million EUR | 0.0% |
| 2023 Q4 | 5.01 Million EUR | 0.0% |
| 2023 FY | 5.01 Million EUR | -20.7% |
| 2022 Q2 | 6.63 Million EUR | 0.0% |
| 2022 FY | 6.32 Million EUR | -5.7% |
| 2022 Q4 | 6.32 Million EUR | 0.0% |
| 2021 Q2 | 7.35 Million EUR | 0.0% |
| 2021 FY | 6.7 Million EUR | -6.67% |
| 2021 Q4 | 6.7 Million EUR | 0.0% |
| 2020 Q2 | 7.36 Million EUR | 0.0% |
| 2020 Q4 | 7.18 Million EUR | 0.0% |
| 2020 FY | 7.18 Million EUR | 33.24% |
| 2019 FY | 5.39 Million EUR | -0.83% |
| 2019 Q4 | 5.39 Million EUR | 0.0% |
| 2019 Q2 | 5.76 Million EUR | 0.0% |
| 2018 Q2 | 1.3 Million EUR | 0.0% |
| 2018 Q4 | 5.43 Million EUR | 0.0% |
| 2018 FY | 5.43 Million EUR | 226.73% |
| 2017 Q2 | 2.85 Million EUR | 0.0% |
| 2017 FY | 1.66 Million EUR | -40.35% |
| 2017 Q4 | 1.66 Million EUR | 0.0% |
| 2016 Q4 | 2.79 Million EUR | 0.0% |
| 2016 FY | 2.79 Million EUR | 165.91% |
| 2015 FY | 1.04 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | 27.428% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 96.172% |
| Adocia SA | 31.87 Million EUR | 84.26% |
| Aelis Farma SA | 13.08 Million EUR | 61.65% |
| Biophytis S.A. | 15.84 Million EUR | 68.35% |
| Advicenne S.A. | 24.37 Million EUR | 79.422% |
| genOway Société anonyme | 14.45 Million EUR | 65.309% |
| IntegraGen SA | 5.97 Million EUR | 16.114% |
| Medesis Pharma S.A. | 6.42 Million EUR | 21.941% |
| Neovacs S.A. | 3.71 Million EUR | -35.13% |
| NFL Biosciences SA | 3.62 Million EUR | -38.543% |
| Plant Advanced Technologies SA | 6.78 Million EUR | 26.041% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -51.542% |
| Sensorion SA | 13.22 Million EUR | 62.077% |
| TME Pharma N.V. | 2.78 Million EUR | -80.115% |
| Valbiotis SA | 13.7 Million EUR | 63.407% |
| TheraVet SA | 1.48 Million EUR | -237.792% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 75.493% |
| argenx SE | 402.79 Million EUR | 98.755% |
| BioSenic S.A. | 32.26 Million EUR | 84.453% |
| Celyad Oncology SA | 9.97 Million EUR | 49.728% |
| DBV Technologies S.A. | 38.74 Million USD | 87.053% |
| Galapagos NV | 1.56 Billion EUR | 99.679% |
| Genfit S.A. | 105.92 Million EUR | 95.264% |
| GeNeuro SA | 20.13 Million EUR | 75.093% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | 41.753% |
| Innate Pharma S.A. | 132.29 Million EUR | 96.208% |
| Inventiva S.A. | 101.59 Million EUR | 95.062% |
| MaaT Pharma SA | 22.46 Million EUR | 77.671% |
| MedinCell S.A. | 77.77 Million EUR | 93.55% |
| Nanobiotix S.A. | 95.74 Million EUR | 94.761% |
| Onward Medical N.V. | 25.69 Million EUR | 80.48% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 80.035% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 91.509% |
| Oxurion NV | 19.73 Million EUR | 74.584% |
| Pharming Group N.V. | 228.28 Million EUR | 97.803% |
| Poxel S.A. | 53.9 Million EUR | 90.694% |
| GenSight Biologics S.A. | 34.72 Million EUR | 85.555% |
| Transgene SA | 26.51 Million EUR | 81.083% |
| Financière de Tubize SA | 123.65 Million EUR | 95.943% |
| UCB SA | 6.56 Billion EUR | 99.924% |
| Valneva SE | 341.14 Million EUR | 98.53% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -10.319% |